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a  b  s  t  r  a  c  t
We  examined  completion  and  compliance  rates  of  rotavirus  (RV)  vaccination  according  to  the  rec-
ommendations  of  the  Advisory  Committee  on  Immunization  Practices  (ACIP)  and the Food  and  Drug
Administration  approved  Prescribing  Information  (PI) for Rotarix® (RV1, GlaxoSmithKline  Vaccines)  and
RotaTeq® (RV5,  Merck  and  Co.)  among  infants  under  one  year  of age  covered  by  Medicaid  programs.
Healthcare  claims  data  from  state  Medicaid  programs  that  constituted  the  Truven  Health  MarketScan®
Multi-State  Medicaid  Database  were  retrieved  from  May 2008–June  2012.  Infants  were  grouped  under  PI
and ACIP  cohorts  based  on  the  dosing  regimens  followed.  The  overall  compliance  per PI (n = 673,956)  and
ACIP  (n = 695,612)  recommendations  were  24.5%  and  28.2%,  respectively;  completion  rates  were  30.3%
and  32.6%,  respectively.  In  the  PI cohort,  infants  who  received  RV1  had  signiﬁcantly  higher compliance  as
compared  with  infants  who  received  RV5  (65.2%  vs.  31.3%;  p < 0.0001);  completion  rates  among  infants
receiving  RV1  and RV5  were  65.3%  and  46.4%,  respectively  (p < 0.0001).  In  the  ACIP  cohort,  compliance
with  RV1  was  signiﬁcantly  higher  than  RV5  (68.8%  vs. 45.9%;  p  < 0.0001)  as  was  the  overall  completion
rate  (73.5%  vs. 48.8%;  p <  0.0001).  While  compliance  is increasing  year  over  year,  overall  compliance  of
RV  vaccines  is  suboptimal,  with  over  40%  of  eligible  infants  unvaccinated  in  both  populations.  The 2-dose
RV  vaccine  showed  better  completion  rates  and  higher  compliance  than  the  3-dose  RV  vaccine  in the
United  States.  Public  health  initiatives  focusing  on  suboptimal  compliance  and  completion  rates  of  RV
vaccination  in the  Medicaid  population  could  improve  these  metrics,  thereby  offering  protection  against
RV  infection.
ublis© 2014  The  Authors.  P
. Introduction
Rotavirus (RV) is one of the leading causes of gastroenteritis (GE)
vomiting and diarrhea) in small children less than ﬁve years of age
1]. Globally, it has been estimated that RV at one time accounted
or nearly 611,000 diarrheal deaths and 39% of diarrheal hospital-
zations in children aged less than ﬁve years annually [2]. Deaths in
he United States (US) were estimated to be uncommon with only
0–40 occurring annually before the initiation of the RV vaccina-
ion program in 2006 [3]. However the direct costs due to RV were
Abbreviations: ACIP, Advisory Committee on Immunization Practices; CDC, Cen-
ers  for Disease Control and Prevention; CPT, Current Procedural Terminology; DTaP,
iphtheria, tetanus toxoids, and acellular pertussis; FDA, Food and Drug Adminis-
ration; GE, gastroenteritis; HMO, Health Maintenance Organization; NIS, National
mmunization Survey; PI, prescribing information; RV, rotavirus; RVGE, rotavirus
astroenteritis; UPP, Universal Purchase Programs; US, United States.
∗ Corresponding author. Tel.: +1 215 751 3267.
E-mail addresses: girishanthy.x.krishnarajah@gsk.com (G. Krishnarajah),
lnara.eynullayeva@truvenhealth.com (E. Eynullayeva).
ttp://dx.doi.org/10.1016/j.vaccine.2014.06.059
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unhed  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
estimated to be $300 million annually with 55,000–70,000 hos-
pitalizations, 200,000 emergency department visits, and 400,000
outpatient visits each year among children less than ﬁve years old
[3]. When indirect costs were added, the total annual costs were
estimated at more than $1 billion [3].
Two  vaccines are currently approved by the Food and Drug
Administration (FDA) for the prevention of rotavirus gastroen-
teritis (RVGE) among infants in the US [4]. The oral pentavalent
vaccine, RotaTeq® (RV5, Merck and Co.) was approved as a three-
dose series in February 2006, and the oral monovalent vaccine,
Rotarix® (RV1, GlaxoSmithKline Vaccines) was approved as a two-
dose series in April 2008. In response to the approval of RV5, the
Centers for Disease Control and Prevention (CDC) Advisory Com-
mittee on Immunization Practices (ACIP) recommended routine
vaccination with RV5 given orally at ages two, four, and six months
in 2006 [4]. However, prescribing information (PI) for RV5 states
the ﬁrst dose is to be given starting at 6–12 weeks of age, with
the subsequent doses given at 4–10-week intervals, and the last
dose should not be given after 32 weeks of age [5]. In 2009, the
ACIP updated these recommendations to include vaccination with
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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V1 given orally at ages two months and four months [6]. The RV1
I, however, states the ﬁrst dose of RV1 is to be given no earlier
han six weeks of age and the second (i.e., last) dose at least four
eeks later, but before 24 weeks of age [7]. A study of adherence
o the 2006 ACIP RV5 dosing schedules for the ﬁrst three months
ollowing vaccine availability found that 51% of infants received
heir ﬁrst dose outside the recommended age window [8]. Another
tudy after the ﬁrst six months of RV vaccine implementation found
0% of infants received their ﬁrst dose outside the recommended
indow [9]. Recent studies also evaluated the rates of adherence
i.e., compliance) to both the ACIP and FDA-approved dosing sched-
les for RV1 and RV5 among infants in the US. One study included
nfants less than one year of age enrolled in managed care plans
nd initiating RV vaccination during the months January to June of
009 [10]. Overall, 61.2% of the population were compliant with
he PI dosing schedules (RV1 75.0% vs. RV5 59.5%; p < 0.001) and
7.2% were compliant with the ACIP dosing schedule (RV1 83.3%
s. RV5 76.4%; p < 0.001). Completion rate, deﬁned as receiving all
oses but not necessarily on schedule, was 84.3% (RV1 91.0% vs.
V5 83.4%; p < 0.001) [10]. Two recent studies on privately insured
hildren also found higher compliance and completion rates among
hildren receiving RV1 than those receiving RV5 [11,12].
The 2012 National Immunization Survey (NIS) released by
he CDC monitored the vaccination coverage among children up
hrough 19–35 months [13]. Signiﬁcant differences were found
y race (White 70.5% vs. Black 60.4%; p < 0.05) and poverty status
below pervert level 63.4% vs. above poverty level 71.6%; p < 0.05)
13]. In a large privately-insured population, between 78 and 83%
f eligible infants received at least one RV vaccine per month in
009–2010 [11]. Both Panozzo et al. [11] and Krishnarajah et al. [12]
ound that among infants receiving at least one rotavirus vaccine,
he completion rate was higher among those receiving RV1 as com-
ared to those receiving RV5 (Panozzo et al: 87% vs.79%, p < 0.01;
rishnarajah et al: 91% vs. 83%, p < 0.01). There is currently no infor-
ation on completion or compliance rates of RV vaccination within
he Medicaid population. The purpose of the current study there-
ore was to examine RV vaccination completion and compliance
ates with both the ACIP recommendations and FDA approved PI
chedule overall and for RV1 and RV5 separately among infants
ess than one year of age enrolled in a large number of Medicaid
rograms. This study also estimated the proportion of infants who
emained unvaccinated and identiﬁed the possible infant and plan
evel predictors of compliance with the PI.
. Methods
.1. Data source
This study was  a retrospective observational cohort study using
dministrative healthcare claims data from state Medicaid pro-
rams that constituted the Truven Health MarketScan® Multi-State
edicaid Database for the period May  1, 2008 to June 30, 2012.
he database reﬂects the healthcare service use (medical and phar-
acy claims) of over 6.7 million individuals covered by Medicaid
rograms in 10–13 geographically dispersed states within a given
ear. Medicaid data were collected from states with and with-
ut Universal Purchase Programs (UPP). Because of conﬁdentiality
greements, we  are unable to reveal the states, but were able
o identify the UPP status of the states that contributed to the
atabase. Enrollees were those covered under fee-for-service and
anaged care plans, for whom monthly eligibility data, federal aid
ategory data (i.e., income based, disability, temporary assistance
or needy families) and racial information were available. Due to
ontractual obligations, the speciﬁc states contributing data to the
atabase were not reported.e 33 (2015) 479–486
2.2. Study populations
Due to differences in PI and ACIP recommendations for the
administration schedule of rotavirus vaccines, two separate popu-
lations of infants were deﬁned. Separate analyses were conducted
for the following cohorts: all states (i.e., both UPP  and non-UPP
states), and non-UPP states only. Age at the time of RV vaccination
was based on the service date on the claim for the ﬁrst dose and the
birth date. Vaccine type was identiﬁed by the Current Procedural
Terminology (CPT) codes on outpatient medical claims.
2.2.1. PI population
Infants in the PI population, born between May  1, 2008 and
December 31, 2011 were identiﬁed and grouped into three cohorts:
(1) infants with at least one claim for RV1 (RV1-PI);
(2) infants with at least one claim for RV5 (RV5-PI); and
(3) infants not receiving any doses of RV1 or RV5.
Eligible infants were further required to have continuous enroll-
ment in medical and pharmacy beneﬁts for at least 24 weeks from
birth for the RV1 cohort and for at least 32 weeks from birth for
the RV5 cohort. Infants who had evidence of receiving more than
one brand (RV1 and RV5) of vaccine in their series were excluded
from the PI cohorts. Infants who had received RV1 or RV5 before
six weeks of age were also excluded.
2.2.2. ACIP population
Infants of the ACIP population selected for analysis were born
between May  1, 2008 and October 31, 2011 and continuously
enrolled in medical and pharmacy beneﬁts from birth to eight
months of age. Infants receiving a mixed regimen of RV vaccines
(at least one dose of RV1 and one dose of RV5) were included. Four
cohorts identiﬁed for the ACIP analysis were:
(1) infants with at least one claim for RV1 and no claims for RV5;
(2) infants with at least one claim for RV5 and no claim for RV1;
(3) infants with claims for both RV1 and RV5 [6]; and
(4) infants who  did not have evidence of receiving either RV1 or
RV5.
Infants who had received RV1 or RV5 before six weeks of age
were excluded.
2.3. Compliance and completion
Compliance to each RV dose was  assessed in accordance with the
corresponding PI or ACIP schedules as described in Table 1. Individ-
ual infants were categorized as “compliant” if he/she received all
doses in accordance with the recommended schedule.
Completion was deﬁned as receipt of two  doses of RV1, three
doses of RV5, or for the ACIP-mixed cohort one dose of RV1 and
two doses of RV5 in any order. Whether infants received three doses
of diphtheria, tetanus toxoids, and acellular pertussis (DTaP) vac-
cine was also assessed. The DTaP vaccine was selected because the
recommended timing overlaps with the ﬁrst 2 (2 months and 4
months) or 3 (2 months, 4 months and 6 months) doses of rotavirus
vaccine.
2.4. Statistical analysesBaseline characteristics were summarized by population (PI or
ACIP) and cohort (RV1, RV5, Mixed, None) using frequency and
percentage for categorical variables and mean and standard devia-
tion for continuous variables. Statistical signiﬁcance was  evaluated
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Table  1
Rotavirus vaccine dosing schedules.
Vaccine dose Recommendations
PIa ACIPb
RV5 RV1
Minimum age for ﬁrst dose 6 Weeks + 6 days 6 Weeks + 6 days 6 Weeks
Maximum age for any dose 32 Weeks 24 Weeks 8 Months and 0 days
Dose  1 6 Weeks through 12 weeks 6 Weeks through 20 weeks 6 Weeks through 14 weeks and 6 days
Dose  2 4–10 Weeks after the previous dose ≥4 Weeks after the previous dose Age 4 months and ≥4 weeks after the previous dose
Dose  3 4–10 Weeks after the previous dose N/A 6 Months and ≥4 weeks after the previous dose
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aa Prescribing information approved by the Food and Drug Administration.
b Advisory Committee on Immunization Practices.
sing chi-square tests and one-way analysis of variance. Differ-
nces were considered statistically signiﬁcant if the two-sided
-value was 0.05 or less.
Predictors of PI compliance for RV vaccination were identiﬁed
sing multivariable log-binomial models on RV1 and RV5 cohorts.
he primary predictors of interest were vaccine received (RV5 was
sed as the reference group) and year of birth; and interactions
etween vaccine type and year of birth. Other covariates included
ere gender, plan type, race, and an indicator of receipt of three
oses of diphtheria, tetanus toxoids, and acellular pertussis (DTaP)
accine. The risk ratios of the parameter estimates with 95% conﬁ-
ence intervals are presented for all model predictors.
All analyses were run separately for all identiﬁed infants and
hose infants not living in Medicaid states with UPP that included
V1 and RV5.
. Results
While analyses of infants residing in all available states and only
n non-UPP states were both conducted, results were similar. In
ddition, infants from non-UPP states accounted for over 90% of
ligible infants from all states. As such, only the results for the non-
PP resident population are presented here.
.1. PI population
Of the 673,956 infants who qualiﬁed for the PI population 51%
ere male; 59.3% were enrolled in capitated Health Maintenance
rganization (HMO) plans, 40.7% fee-for-service (of which 0.9%
ere of other/unknown plans); 49.4% were White, 32.5% Black, 6.0%
ispanic, and 2.8% other and 9.3% of unknown race.
Nearly 43% of infants (n = 287,676) did not have claims for either
V1 or RV5 but the proportion of unvaccinated infants declined
rom 50% in 2008 to 33% in 2011. On analysis by race, more than
ne-half of Hispanic infants were unvaccinated (54%), followed by
lack (45%) and White (39%) infants (p < 0.0001) (Table 2).
Overall, 57% (n = 386,280) of the PI population received RV vac-
ination. Speciﬁcally, 19% (n = 130,928) had one or more claims for
V1 and 38% (n = 255,352) had one or more claims for RV5. The pro-
ortion of infants vaccinated with at least one dose of RV1 increased
rom 2% in 2008 to 30% in 2011 and those with at least one dose of
V5 decreased from 49% in 2008 to 38% in 2011.
In the PI population, 24.5% (n = 165,322) were fully compli-
nt and compliance rate increased from 2008 (19.2%) to 2011
32.6%). Hispanic infants had the lowest identiﬁed rate of compli-
nce (16.9%), followed by black infants (21.6%), and White infants
28.5%; p < 0.0001). No differences in compliance by infant gender
ere found.
When stratiﬁed by RV type, infants who received the ﬁrst dose
f RV1 had a signiﬁcantly higher compliance rate than infants who
eceived the ﬁrst dose of RV5 (65.2% vs. 31.3%; p < 0.0001). Evalu-
ting non-compliance by dose, the RV5 cohort had a signiﬁcantlyhigher rate of ﬁrst dose non-compliance compared with the RV1
cohort (20.1% vs. 1.9%; p < 0.0001). Similarly, non-compliance with
the second dose was signiﬁcantly higher in the RV5 (49.2%) com-
pared with the RV1 (34.8%; p < 0.0001) cohort (Table 2).
Less than a third (30.3%) of infants completed all required doses
of RV vaccines. Completion rates among infants receiving RV1 were
1.4 times those receiving RV5. Among infants receiving RV1 65.3%
completed both doses, and among infants receiving RV5, com-
pletion of all three doses was  46.4% (p < 0.0001). While, RV5-PI
completion was  less than 50%, of the 255,352 infants having at least
one RV5 dose, 79.1% (n = 202,066) received at least the second dose
and among these, 58.6% (n = 118,467) received the third dose.
Results of the multivariable analysis evaluating predictors of PI
compliance are presented in Table 3. Infants who received DTaP
vaccination had a higher likelihood of RV vaccination-PI compliance
(risk ratio = 17.8 [95% conﬁdence interval: 17.4–18.3]). For infants
born in 2008, those receiving one dose of RV1 were 1.4 times as
likely to be compliant as those receiving at least one dose of RV5.
3.2. ACIP population
After applying the ACIP criteria for cohort selection, 118,555
(17%) subjects received RV1; 250,188 (36%) subjects received RV5;
46,067 (6.6%) had claims for both RV1 and RV5 vaccines (mixed);
and 280,802 (40.4%) did not have claims for either RV vaccine.
Results for the ACIP population (n = 695,612) were largely similar
to those of the PI population. The majority of infants were White
(49.8%) followed by Black (32.6%) and Hispanic (5.8%). Almost all
infants received RV vaccines also received DTaP vaccination (99.4%
in RV1 cohort and 98.2% in RV5 cohort) (Table 4).
Overall 40.4% of the ACIP population did not receive RV vaccines,
and the proportion decreased from 48% in 2008 to 32% in 2011
(p < 0.0001). The highest proportion of unvaccinated infants in the
ACIP population was  observed in Hispanic infants (52%), followed
by Black (42%) and White (36%) infants (p < 0.0001) (Table 4).
Over a quarter (28.2%, n = 196,500) of ACIP population were fully
compliant and compliance rate for RV1 recipients (68.8%) was sig-
niﬁcantly higher than that for RV5 recipients (45.9%; p < 0.0001)
(Table 4). Overall completion rate of RV vaccination was 32.6%
(n = 226,537). The completion rate in RV1 cohort was  1.5 times as
RV5 cohort: 73.5% of RV1 cohort completed two  required doses,
and 48.8% of the RV5 cohort completed three required doses. In
the mixed cohort, 37.9% of the infants completed all three required
doses (p < 0.0001).
4. Discussion
The goal of the current analysis was to examine compliance,
and completion rates of rotavirus vaccination overall and by type
of vaccine (Rotarix® and RotaTeq®) based on FDA package insert
and CDC-ACIP recommendations, and predictors of overall PI com-
pliance among infants enrolled in Medicaid health plans. Results
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Table 2
Compliance to dosing schedule per PI and completion rates (na = 673,956).
Compliance per PI and
completion
All infants (nb = 673,956) RV1 (n = 130,928) RV5 (n = 255,352) Infants with No RV
vaccine (n = 287,676)
p-Valued RV1
vs. RV5
n %c n % n % n %
Age in weeks at
initiation (Mean,
SDe)
11.1 4.4 10.7 3.4 11.3 4.8 NAf NA <0.0001
Age  in weeks at
completion (Mean,
SD)
23.7 4.6 18.6 1.7 27.3 1.7 NA NA <0.0001
Vaccinations rates (n, %)
Overall 673,956 100.0 130,928 19.4 255,352 37.9 287,676 42.7
<0.0001
By  birth year
2008 122,561 100.0 2456 2.0 59,381 48.5 60,724 49.5
2009  205,006 100.0 39,781 19.4 67,164 32.8 98,061 47.8
2010  183,516 100.0 40,161 21.9 67,568 36.8 75,787 41.3
2011  162,873 100.0 48,530 29.8 61,239 37.6 53,104 32.6
By  race
<0.0001White 333,012 100.0 69,688 20.9 135,039 40.6 128,285 38.5
Black  218,833 100.0 45,830 20.9 75,614 34.6 97,389 44.5
Hispanic 40,328 100.0 3741 9.3 14,905 37.0 21,682 53.8
Other  19,193 100.0 3962 20.6 8482 44.2 6749 35.2
Unknown 62,590 100.0 7707 12.3 21,312 34.1 33,571 53.6
Infants fully compliant (n, %)
Overall (n, %) 165,322 24.5 85,376 65.2 79,946 31.3 NA NA <0.0001
By  birth year
2008 23,591 19.2 1426 58.1 22,165 37.3 NA NA <0.0001
2009 41,525 20.3 24,502 61.6 17,023 25.3 NA NA <0.0001
2010 47,056 25.6 26,192 65.2 20,864 30.9 NA NA <0.0001
2011  53,150 32.6 33,256 68.5 19,894 32.5 NA NA <0.0001
By  race
White 94,851 28.5 47,382 68.0 47,469 35.2 <0.0001
Black 47,287 21.6 28,451 62.1 18,836 24.9 NA NA
Hispanic 6812 16.9 2100 56.1 4712 31.6
Other  5333 27.8 2653 67.0 2680 31.6 NA NA
Unknown 11,039 17.6 4790 62.2 6249 29.3
Infants who are non-compliant, by dose (n, %)
Number of infants who
were non-compliant
with the ﬁrst dose
53,773 8.0 2480 1.9 51,293 20.1 NA NA <0.0001
Number of infants who
were non-compliant
with the second dose
171,227 25.4 45,552 34.8 125,675 49.2 NA NA <0.0001
Number of infants who
were non-compliant
with the third dose
175,406 26.0 NA NA 175,406 68.7 NA NA
Completion rate (n, %)
Infants who completed
all doses
203,952 30.3 85,485 65.3 118,467 46.4 NA NA <0.0001
By  dose
Number of infants who
received only the
ﬁrst dose
98,729 14.6 45,443 34.7 53,286 20.9 NA NA <0.0001
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Table  2 (Continued)
Compliance per PI and
completion
All infants (nb = 673,956) RV1 (n = 130,928) RV5 (n = 255,352) Infants with No RV
vaccine (n = 287,676)
p-Valued RV1
vs. RV5
n %c n % n % n %
Number of infants who
received the ﬁrst and
the second doses
only
83,599 12.4 85,485 65.3 83,599 32.7 NA NA
Number of infants who
received the ﬁrst,
second and third
doses
NA NA NA NA 118,467 46.4 NA NA <0.0001
a Total number of infants.
b Number of infants in each category.
c Percentage of infants in each category.
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Nd p-Value calculated using chi-square tests and one-way analysis of variance.
e Standard deviation.
f Not applicable.
how that despite increasing national vaccination coverage for RV
accines, a sizeable proportion of Medicaid infants in the states
roviding data to the study database either do not get vaccinated
t all or do not receive their vaccinations according to either of the
ecommended schedules. Racial disparities also exist with more
han one-half of Hispanic infants being unvaccinated while 39%
f White infants were not vaccinated between 2008 and 2011.
n addition disparities exist depending on the type of health plan
nfants are enrolled in, with fee-for-service plans having greater
on-vaccination rates than those enrolled in HMOs.
In our study, overall RV vaccination compliance rate was  found
o be 24.5% per PI and 28.2% per ACIP recommendation; the overall
ompletion rate was 30.3% in the PI population and 32.6% in the
CIP population. While not largely different from each other, more
atients were compliant to ACIP recommendations potentially due
o efforts to harmonize a single dosing schedule. While overall com-
letion rates were relatively low, getting the ﬁrst vaccine in the
eries was found to increase the chances of getting the second (for
V1 and RV5) and third (for RV5) doses. In the PI population, we
ound 43% of infants without either RV1 or RV5 vaccines and in
he ACIP population the proportion of unvaccinated infants was
0%. Compliance and completion per PI and ACIP recommendations
able 3
ultivariate model of PI compliance with interaction terms.
Variable Rela
RV1 1.40
Female 0.99
Birth  year (r
Year 2009 0.79
Year  2010 0.88
Year  2011 0.92
Race  (ref =
Black 0.95
Hispanic 0.98
Other  race 0.99
Missing race 0.99
Plan  type (ref = co
Health Maintenance Organization (HMO) 0.99
Unknown plan type 1.03
3-Dose DTaP vaccines within 24 (RV1) or 32 weeks (RV5 or neither) 17.8
Vaccine × year
RV1  × year 2009 1.22
RV1  × year 2010 1.20
RV1  × year 2011 1.20
ote: sample is restricted to non-UPP infants.
a p-Value calculated using chi-square tests and one-way analysis of variance.were both found to be signiﬁcantly greater among infants receiving
RV1 than those receiving RV5.
These results are in contrast to those reported by the NIS which
estimates RV vaccination coverage between Q1 2012 and Q4 2012
in infants born between January 2009 and May  2011. The survey
found approximately 68.6% of participants to have received either
two doses of RV1 or all three doses of RV5 [13]. The NIS sample
included infants enrolled in privately and publicly sponsored health
plans as well as infants who were uninsured or under insured.
While there may  be some selection bias associated with the NIS,
the mix  of payers may  account for much of the discrepancy. Fur-
thermore, the children included in the survey were older (19–35
months) [13] than those included in our study (6–8 months), which
may  further explain the difference in coverage rates. However, the
difference in RV vaccination coverage by poverty status and racial
background observed in our study was similar to that reported in
the NIS [13].
According to the 2012 Annual Report on the Quality of Care
for Children in Medicaid and Children’s Health Insurance Pro-
gram, younger children with public coverage appear to lag behind
privately insured children on rates of well-child visits and immun-
izations [14]. The reasons for this are numerous but infants
tive risk 95% Conﬁdence interval
around relative risk
p-Valuea
2 1.371–1.433 <0.001
9 0.995–1.002 0.470
ef = 2008)
4 0.783–0.805 <0.001
5 0.873–0.896 <0.001
8 0.916–0.940 <0.001
 white)
7 0.952–0.961 <0.001
0 0.970–0.989 <0.001
3 0.983–1.003 0.147
2 0.985–0.999 0.031
mprehensive)
9 0.995–1.002 0.488
3 1.010–1.057 0.004
05 17.336–18.287 <0.001
 interaction
8 1.197–1.260 <0.001
5 1.176–1.235 <0.001
8 1.179–1.237 <0.001
484
 
G
.
 K
rishnarajah
 et
 al.
 /
 V
accine
 33
 (2015)
 479–486
Table 4
Compliance to dosing schedule per ACIP and completion rates (na = 695,612).
Compliance per ACIP
and completion
Infants who  had at
least 1 RV vaccine
(nb = 414,810)
RV1 (n = 118,555) RV5 (n = 250,188) p-Valuee RV1
vs. RV5
Mixed RV1 and
RV5
(n = 46,067)
p-Value RV1 vs.
RV5 vs. Mixed
Infants with No RV
vaccine
(n = 280,802)
n %c n % n % n % n %
Receipt of other vaccines (n, %)
DTaP  vaccination (any) 409,646 58.9 117,836 99.4 245,774 98.2 <0.0001 46,036 99.9 <0.0001 70,242 25.0
DTaP  vaccination (completed) 255,507 36.7 73,176 61.7 146,940 58.7 <0.0001 35,391 76.8 <0.0001 22,036 7.8
Age  in weeks at initiation (Mean, SD)d 11.2 4.6 11.2 4.3 11.4 4.9 <0.0001 9.9 2.5 <0.0001 NA NA
Age  in weeks at completion (Mean, SD) 24.5 4.7 19.6 3.3 27.6 2.0 <0.0001 27.7 2.3 <0.0001 NA NA
Vaccination rates
Overall 695,612 118,555 17.0 250,188 36.0 46,067 6.6 280,802 40.4
By  birth year
2008 125,425 100.0 2505 2.0 59,176 47.2 <0.0001 3527 2.8 <0.0001 60,217 48.0
2009  219,129 100.0 37,173 17.0 66,578 30.4 18,392 8.4 96,986 44.3
2010  195,218 100.0 39,251 20.1 67,305 34.5 14,276 7.3 74,386 38.1
2011  155,840 100.0 39,626 25.4 57,129 36.7 9872 6.3 49,213 31.6
By  race
White 346,499 100.0 63,623 18.4 132,475 38.2 <0.0001 25,075 7.2 NA 125,326 36.2
Black  226,900 100.0 41,452 18.3 73,983 32.6 16,211 7.1 NA 95,254 42.0
Hispanic 40,382 100.0 3449 8.5 14,662 36.3 1172 2.9 NA 21,099 52.2
Other  19,809 100.0 3556 18.0 8325 42.0 1390 7.0 NA 6538 33.0
Unknown 62,022 100.0 6475 10.4 20,743 33.4 2219 3.6 NA 32,585 52.5
Infants fully compliant (n, %)
Overall 196,500 28.2 81,594 68.8 114,906 45.9 <0.0001 NA NA NA NA NA
By  birth year
2008 34,016 27.1 1400 55.9 32,616 55.1 <0.4471 NA NA NA NA NA
2009  50,040 22.8 25,220 67.8 24,820 37.3 <0.0001 NA NA NA NA NA
2010  57,496 29.5 26,810 68.3 30,686 45.6 <0.0001 NA NA NA NA NA
2011  54,948 35.3 28,164 71.1 26,784 46.9 <0.0001 NA NA NA NA NA
By  race
White 112,289 32.4 45,475 71.5 66,814 50.4 NA NA NA NA NA NA
Black  56,409 24.9 27,626 66.6 28,783 38.9 NA NA NA NA
Hispanic 8756 21.7 1909 55.3 6847 46.7 NA NA NA NA NA NA
Other  6205 31.3 2474 69.6 3731 44.8 NA NA NA NA NA NA
Unknown 12,841 20.7 4110 63.5 8731 42.1 NA NA NA NA NA NA
Infants  who are non-compliant, by dose (n, %)
Number of infants who missed the ﬁrst dose 60,622 8.7 18,750 15.8 41,872 16.7 <0.0001 NA NA NA NA NA
Number  of infants who missed the second dose 111,664 16.1 36,961 31.2 74,703 29.9 <0.0001 NA NA NA NA NA
Number  of infants who missed the third dose 135,282 19.4 135,282 54.1 NA NA NA NA NA
Infants who completed their doses (n, %)
Number of infants who received all doses 226,537 32.6 87,085 73.5 121,973 48.8 <0.0001 17,479 37.9 <0.0001 NA NA
Number  of infants who received only the ﬁrst
dose
81,862 11.8 31,470 26.5 50,392 20.1 <0.0001 NA NA NA NA NA
Number  of infants who received the ﬁrst and
the second doses only
77,823 11.2 87,085 73.5 77,823 31.1 NA NA NA NA NA NA
Number  of infants who ﬁrst, second and third
doses
NA NA NA NA 121,973 48.8 <0.0001 17,479 37.9 <0.0001 NA NA
a Total number of infants.
b Number of infants in each category.
c Percentage of infants in each category.
d Standard deviation.
e p-Value.
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[6] Cortese MM,  Parashar UB. Prevention of rotavirus gastroenteritis among infants
and children, recommendations of the Advisory Committee on ImmunizationG. Krishnarajah et al. /
ith Medicaid coverage are less likely to have a usual health-
are provider with night or weekend hours and their parents
r guardians are less likely to have transportation to the doc-
or’s ofﬁce or clinic [15,16]. These barriers not only impact the
eceipt of vaccination but also the timing of vaccinations. While
ot a focus of this analysis, RV vaccination results as compared to
hose reported in the NIS are similar to results of DTaP immuni-
ation in the two datasets. The DTaP completion rate in this study
as 36.7% by 32 weeks (eight months) whereas the reported NIS
ompletion rate was 69.7% by seven months of age [17]. These
esults suggest that the differences observed for RV vaccination
re not unique and the reasons underpinning these discrepancies
re again largely based on differences in the underlying popula-
ions. After accounting for other infant and plan characteristics,
nfants completing the DTaP vaccination series were more likely
o be compliant with RV vaccination. In the unadjusted analyses,
ollowing the receipt of the ﬁrst dose of RV vaccine, compliance
ith the ﬁrst dose of either RV1 or RV5 resulted in high propor-
ions of infants receiving the second dose of either, and among
hose on the 3-dose regimen, subsequently completing the vaccine
chedule.
Interestingly, in the PI population non-compliance for the ﬁrst
ose of RV1 was signiﬁcantly lower compared with RV5 (1.9% vs.
0.1%; p < 0.0001). One explanation for this large difference could
e attributable to the recommended time windows for giving the
rst dose listed in the each of the PIs as the window for giving the
rst RV1 dose is eight weeks wider than that for RV5 (RV1: 6–20
eeks vs. RV5: 6–12 weeks). While assessing the completion of RV,
ess emphasis was given to the timing of individual RV doses than
n the assessment of compliance. The RV1 cohort also had a signiﬁ-
antly higher completion rate than the RV5 cohort (65.3% vs. 46.4%,
 < 0.001) by the age of 8 months, which is mainly attributable to
he fewer doses required by RV1 series.
There are several limitations to these analyses. First, admin-
strative claims data are generated for the purposes of provider
eimbursement and not for this study. Information derived from
edical billing codes may  be subject to omissions, errors, or other
ifferences in billing and reimbursement practices of physician
fﬁces and individual state Medicaid programs. Presence of RV1
nd RV5 was identiﬁed by using CPT codes on medical claims,
s opposed to medical records. There is also the potential for
election bias as a result of the process by which the analytic sam-
le was selected. For example, the continuous eligibility criterion
equires the study infants to have at least eight months of med-
cal and pharmacy beneﬁts from their date of birth. While this
riterion allows for more meaningful comparisons between the
tudy cohorts, those infants who had intermittent healthcare cover-
ge were not examined. As noted, the study population comprised
nfants with Medicaid coverage in the subset of US states contained
n the Truven Health MarketScan® Multi-State Medicaid Database
ith and without UPPs. Thus, the results may  not be representative
f all infants enrolled in all Medicaid programs across the United
tates.
. Conclusion
A large proportion of infants in the US remain unvaccinated.
he proportion of infants that completed the RV vaccination series
as higher among recipients of RV1 than RV5. RV1 recipients also
howed higher compliance with both the PI and ACIP recommen-
ations relative to RV5 recipients. Infants vaccinated with DTaP
accine had a higher likelihood of compliance with RV vaccina-
ion. Despite CDC recommendations, RV vaccine is underutilized
n US Medicaid recipients with as many as 40% of eligible infants
nvaccinated. Public health initiatives to increase completion ande 33 (2015) 479–486 485
compliance with vaccine recommendations may help improve
vaccination initiation, completion and compliance rates among
infants who  need protection against RV infection and reduce the
states cost burden in providing care to infants with RV infec-
tion.
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